Houston-based Zeta Energy has fresh funding from the government. Image via Zeta Energy

Houston-based Zeta Energy announced this week that it was selected to receive $4 million in federal funding for the development of efficient electric vehicle batteries.

The funds come from the U.S. Department of Energy's ARPA-E Electric Vehicles for American Low-Carbon Living, or EVs4ALL, program, which aims to increase the number of EVs on the roads by boosting the country’s supply chain of affordable, convenient, reliable and safe batteries.

Zeta Energy is one of 12 groups in the U.S. to receive funding from the program, which awarded $42 million in total.

“Electric vehicle sales in America have tripled since the start of this Administration and by addressing battery efficiency, resiliency and affordability, the projects announced today will make EVs attractive to even more drivers,” U.S. Secretary of Energy Jennifer M. Granholm said in a statement released earlier this week. “This is a win-win for our efforts to fight climate change and power America’s clean transportation future with technologies produced by researchers and scientists right here at home.”

Other teams to receive funding include 24M Technologies, national laboratories and universities like The Ohio State University, University of Maryland, Virginia Tech, among others. Zeta is the only Texas-based company to receive funds. It received one of the largest grants among the group.

"We are thrilled to have been selected for funding by the ARPA-E EVs4ALL program," Zeta Energy CEO Tom Pilette said in a statement. "We have been working hard to make this technology a reality, and we are really grateful to receive this recognition of the promise of our technology and the progress we have made on it."

Zeta Energy is known for its lithium sulfur batteries that traditionally have not been long lasting. While sulfur is an economical and abundant material, it traditionally would dissolve after a few uses in lithium sulfur batteries.

However, Zeta uses its proprietary sulfur-based cathodes and lithium metal anodes that have shown to have higher capacity and density and better safety profiles, according to the company's website.

According to ARPAE, the company will create a new anode that will "be highly accessible and rechargeable" with the funding.

Zeta Energy

closed a $23 million series A round led by New York VC firm Moore Strategic Ventures about a year ago. In addition to applications for electric vehicles, the company's technology is also expected to have uses in grid energy storage.
Houston-based Zeta Energy has raised fresh funding to grow its Houston operations and further commercialize the company's innovative batteries for electric vehicles and energy storage. Photo via Getty Images

Houston-based battery innovators close $23M series A

money moves

Houston-based Zeta Energy announced this month that it has closed a $23 million series A round led by New York VC firm Moore Strategic Ventures.

The funding will be used to expand Zeta's lab facility in the Houston area and further commercialize the company's innovative batteries for electric vehicles and energy storage.

"We are delighted to have Moore Strategic Ventures join Zeta Energy. Moore's focus on transportation, advanced materials, energy, and clean tech aligns perfectly with Zeta's strategic objectives," Charles Maslin, founder and CEO of Zeta Energy, said in a statement. "We are so excited to work together to help the world transition to clean energy and build a more sustainable future."

Founded in 2014, Zeta develops affordable and sustainable rechargeable batteries and is known for its lithium sulfur battery system. The system utilizes Zeta's proprietary sulfur-based cathodes and lithium metal anodes that have shown to have higher capacity and density and better safety profiles, according to the company's website.

The company is slated to move to a new 12,000-square-foot facility in West Houston in Q2 where it will employ 40 individuals, including 25 researchers, engineers, and developers.

"Houston is the ideal location for us to advance our core battery and materials technology," Zeta COO Tom Pilette said in a statement. "With this new facility we will be able to demonstrate the performance and cost characteristics of our proprietary technology and help accelerate electrification and the transition to green energy and beyond."

The news comes on the heels of Austin-based Tesla revealing details on a new "energy-storage park" South of Houston, equipped with 81 Megapack batteries that store clean energy. The site is predicted to help ease the impact of power grid losses in the state.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”